TrialDrug safety2018

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

Terufumi Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.